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ABSTRACT 
Objectives: to evaluate whether in chronic hepatitis C-positive naïve patients recruited in the routine 
clinical setting and treated with pegylated-interferon-alfa2b (Peg-IFN) and ribavirin (RBV) the sustained 
virologic response (SVR) is durable over the long-term and if it is associated to a decrease of liver 
complications and incidence of glucose abnormalities. 
Methods: prospective long-term follow-up of 182 naïve patients enrolled in 2001-2002 and treated with 
Peg-IFN and RBV and followed up to December 2010 with clinical, biochemical and virological evaluations 
every 6-12 months.  
Results: none of the 115 (63.2%) sustained responders showed late viremic relapse during the follow-up. 
SVR was better defined at 24 weeks (16/16 relapsers, 100%) than at 12 weeks after the end of therapy 
(14/16 relapsers, 87.5%).  At multivariable analysis, viral genotype (OR 0.16, 95% CI 0.07-0.36, p= 0.0001) 
and a >20% RBV reduction (OR 5.21, 95% CI 1.54-17.67, p= 0.008)  independently predicted long-term 
response (LTR). Incidence of cirrhosis was significantly higher among non responders (21.3%) compared 
with long-term responders (0.9%,  p≤0.0001) but risk of developing glucose abnormalities was not 
significantly reduced in long-term responders (HR=1.36, p= 0.363).  Hepatocellular carcinoma occurred in 
three cases only. 
Conclusions: SVR obtained in patients treated in the routine clinical setting with Peg-IFN and RBV is durable 
over the long-term and LTR significantly reduces the risk of progression to cirrhosis; however, in a 
population with mild liver fibrosis the clinical impact of LTR on the risk of glucose abnormalities seems 
negligible.   
 
 
 
 
 
 
INTRODUCTION 
Despite well established response rates in patients with chronic hepatitis C treated with standard 
Interferon (IFN) with or without ribavirin (RBV) in international controlled trials (1-5), knowledge is still 
incomplete regarding the long term clinical, virologic, histologic outcomes in the clinical setting. Even more 
limited data exist regarding the long term durability of a sustained virologic response (SVR) following 
Pegylated-IFN (Peg-IFN) treatment (6-9).  In particular, the risk of late virologic relapse and late 
complications of HCV infection (decompensated liver disease, hepatocellular carcinoma) after treatment 
courses with Peg-IFN and RBV are scarcely known and the few studies which addressed these issues either 
come from randomized controlled trials (6,9) or have a retrospective design (8) without fully reporting the 
type of patients recruited.  Moreover, these studies used HCV-PCR assays with different degrees of 
sensitivity and heterogeneous patients populations, resulting in variable late relapse rates, ranging from 0% 
to 8.7%.  The wide range of  sensitivity regarding Hepatitis C Virus -RiboNucleic Acid (HCV-RNA) testing may 
also account for the controversy concerning the optimal timing for the definition of SVR: according to a 
recent study (10) assessment of serum HCV-RNA 12 weeks after the end of treatment is as relevant as after 
24 weeks to predict SVR but this conclusion was not confirmed by a Japanese study (11).   
Finally, the clinical impact of HCV eradication on the incidence of glucose metabolism derangements is still 
unclear.  Curing HCV seems to have beneficial effects on the level of insulin sensitivity (12,13) and to 
significantly reduce the incidence of diabetes mellitus (DM) (14,15), although this may not be the rule (16). 
Primary aims of this study were 1) to determine the durability of  SVR in patients recruited in the clinical 
setting and treated with Peg-IFN alfa2b and ribavirin, comparing the clinical outcome of patients with a 
long-term response (LTR) with that observed in non responders (NR)/relapsers (RR) 2) to estimate the 
cumulative incidence rate of glucose abnormalities in patients with and without  LTR. 
Secondary aim was  to establish  if measurement of serum HCV-RNA at 12 weeks post-treatment   to assess 
LTR is as relevant as at 24 weeks post-treatment in patients with an end of treatment response (ETR).  
To answer these questions, we prospectively followed up from 2001 up to 2010 182 chronic hepatitis C 
naive (CHC) patients recruited in the routine clinical setting treated with Peg-IFN alfa2b plus RBV. 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
PATIENTS AND METHODS 
Between March 2001 and March 2002, all naive patients with histologically proven chronic hepatitis C 
consecutively collected in 8 Hepatologic Units of North Western of Italy who fulfilled the inclusion criteria 
were asked  to participate into this prospective cohort study.  
Inclusion criteria were: age > 18 years; positive results for HCV-RNA by polymerase chain reaction (PCR); 
CHC at liver biopsy; documented baseline informations regarding: gender, Body Mass Index (BMI), viral 
load, genotype, liver function tests, liver histologic staging, glucose. Exclusion criteria were: age > 65 years, 
inclusion in trials with IFN-based and ribavirin therapies, major contraindications to IFN or RBV therapy, 
haemoglobin level < 12 g/dL, platelet count < 100000/mm3, granulocyte count < 1500/mm3, 
decompensated liver disease, active alcohol intake, psychoactive legal and illegal drug abuse, presence of 
other concomitant diseases or conditions representing a contraindication to therapy, unwillingness to 
participate or to give consent.  
Since the only pegylated interferon licensed in Italy and reimbursed by the National Health  System in 2001 
was pegylated interferon alfa2b (Peg-Intron, Schering Plough, USA), each patient was treated with Peg-IFN 
(1.5 g/kg once weekly) plus RBV (800-1200 mg/daily) for 24 or 48 weeks according to genotype (genotype 
2-3: 24 weeks, genotype 1 and 4: 48 weeks). 
When severe side effects occurred, the dose of Peg-IFN was decreased by 20%-50% and the dose of RBV 
was lowered to 600-800 mg daily, depending on the baseline dosage. 
 After week 24 post-treatment, all patients were followed up every 6 months for the first 3 years and once 
a year thereafter if they achieved a sustained response. NR/RR and cirrhotics were followed up every six 
months.  Routine follow-up studies included clinical assessment, conventional biochemical tests, HCV-RNA 
detection and HCC screening using serum alfafetoprotein and liver ultrasonography.  The starting date of 
follow-up for each patient began at the end of antiviral treatment. The end of follow-up was the date of 
death or the closing date of the study, December 31, 2010, or the date of the last available visit for 
patients lost to follow-up.  At the last follow-up visit, each patient was invited to undergo transient 
elastography. 
A sustained virologic response (SVR) was defined as the HCV-RNA clearance 24 weeks after the end of 
treatment.  Patients who maintained viral eradication throughout the follow-up were defined as long-term 
responders (LTR).  Patients who did not show HCV-RNA clearance at the end of therapy were considered 
NR; those who showed a viral reactivation after 12 or 24 weeks after treatment were defined as RR.  The 
median duration of follow-up was  years (interquartile range, IQR: 9.0-9.5).  Written informed consent 
was obtained from all the patients prior to recruitment. The study protocol conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki and was approved by our local Ethical Committee. 
 
Definitions 
According to the criteria recommended by the Expert Committee on the Diagnosis and Classification of 
Diabetes Mellitus, diabetes was defined as fasting plasma glucose ≥ 126 mg/dl (7 mmol/l) in two separate 
measurements and impaired fasting glucose (IFG) was defined as baseline glucose levels 100-125 mg/dl 
(5.6-6.9 mmol/l) (17). 
 
Virology 
At baseline, genotypes were identified using a line probe hybridization assay (Line Probe assay, LIPA HCV, 
Innogenetics, Zwijndrecht, Belgium).  Immediately before the inclusion into the study, HCV-RNA was 
quantified by a branched-DNA assay (Quantiplex, Bayer Diagnostics, Tarrytown, NY, USA) with a lower limit 
of detection of 615 IU/ml.  Serum samples below this cut-off were evaluated for HCV-RNA by the COBAS-
AMPLICOR assay (Roche Diagnostic Systems, Branchburg, NJ, USA) which had a sensitivity of 50 IU/ml.  The 
COBAS AMPLICOR assay was also used to test viraemia in each patient at the end of therapy and during 
follow-up until the advent of a more sensitive assay using real-time PCR-based methods (Cobas 
Taqman/CAP-CTM, Roche Molecular Systems, Basel, Switzerland) with a limit of detection of 15 UI/ml.   
Liver-related events 
Patients were considered to have liver failure if they met any of the following criteria: ascites confirmed by 
ultrasound or computed tomography (CT), bleeding oesophageal varices, jaundice with bilirubin > 35 
µmol/L or hepatic encephalopathy.  Patients were considered to have HCC if the diagnosis was cyto-
histologically confirmed, or if two coincident imaging techniques (ultrasound, CT or magnetic resonance 
imaging) showed a focal lesion > 2 cm with arterial hypervascularization or if one imaging technique 
showed a focal lesion > 2 cm with arterial hypervascularization in the presence of  alpha-fetoprotein > 400 
ng/ml. 
 Histology 
The degree of liver fibrosis was assessed blindly by one pathologist according to the Ishak scoring system  
(18).  During the follow-up, subjects were classified as cirrhotic by a second liver biopsy or, in the absence 
of bioptic examination, if they showed unequivocal evidence of portal hypertension (presence of 
esophageal varices not associated with portal vein thrombosis),  or a particular ultrasound pattern (nodular 
contour, diminished hepatopetal flow, collaterals) or a typical serology (platelets < 80000/mm3, albumin < 
3.5 g/l, clotting factors < 50%) or by liver elastography adopting the stringent recommendations suggested 
by Kettaneh et al. and showing a liver stiffness > 14.5 KPascal (19). 
 
Statistical analysis 
Patients’ characteristics at baseline were described with means and standard deviations (or with medians 
and inter quartile ranges if not normally distributed) or with frequencies (and percentages).  To analyze the 
prognostic role of clinical and virological features on LTR we used logistic regression models (since after 
the first 24 weeks after the end of therapy  no relapses have  occurred during the rest of follow up), 
including all relevant baseline characteristics chosen “a priori”, without any further selection.  The 
association between the long-term virological response and the development of  clinical outcomes at the 
end of follow-up (cirrhosis, HCC) was assessed with the Fisher exact test.  The risk of developing IFG or DM 
during the follow-up was estimated in 151 patients with normal glycemic values at baseline and with a 
complete follow-up.  We estimated the cumulative incidence of IFG or DM with the Kaplan Meier method, 
since no competing events occurred during the follow-up.  To explore the role of the baseline patients' 
characteristics on the risk of occurrence of IFG or DM we compared the survival curves with the log-rank 
test.  Separate  Cox proportional hazard models were then fitted for each explanatory variable, including 
as potential confounders age (in years) and baseline viral load (in log IU/ml) in all models, since these 
two variables were the strongest predictors of the outcome and the limited number of failures analysed 
(n= 19) prevented a more careful adjustment.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
Of 224 consecutively collected naïve patients, 182 (81.2%) accepted to participate into the study; of the 
remaining 42 (18.8%), 28 did not fulfil inclusion/exclusion criteria and 14 did not give their informed 
consent.  Demographic, clinical, virological and histological features of recruited patients are reported in 
Table 1.  Out of 182 patients, 131 (72%) were HCV-RNA-negative at the end of therapy while 51 (28%) were 
non responders. Viremic relapse was observed in 16 of 131 (8.8%), 14 at 12 weeks and 2 at 24 weeks after 
the end of therapy.     Overall, 115 (63.2%) patients were sustained responders and none showed late 
relapse during the follow up.  Of 182 enrolled patients, 11 (6%) prematurely discontinued treatment due to 
side effects and were lost to long term follow-up; four of them showed IGF/DM at baseline.  
  Thirty-nine (44.8%) of 87 genotype 1 patients, 45 (86.5%) of  52 genotype 2 patients, 26 (81.2%) of 32 
genotype 3 patients and 5 (45.4%) of 11 genotype 4 patients were LTR; a significant difference in outcome 
between unfavourable (1-4) and favourable (2-3) genotypes was observed (44.9%  vs 84.5%, OR 0.15,  95% 
CI 0.07-0.30, p= 0.0001). Other baseline features associated to LTR are reported in Table 2.  Patients with a 
LTR were younger than NR/RR and showed a lower viral load and BMI at baseline; a >20% reduction of Peg-
IFN dosage negatively influenced the LTR.   The presence of IFG or overt DM was associated with a lower 
LTR rate (37.5% vs 67.1%, OR 0.29, 95% CI 0.12-0.72, p=0.007). At the multivariable logistic regression 
analysis (Table 2), most of the variables showed weaker associations with LTR and only the viral genotype 
(OR 0.16, 95% CI 0.07-0.36, p= 0.0001) and a >20% RBV reduction (OR 5.21, 95% CI 1.54-17.67, p= 0.008)  
strongly  predicted LTR. 
Out of 168 patients without baseline cirrhosis, 14 (8.3%, 95% CI 5.03-13.50) developed cirrhosis throughout 
the follow up.  Among 107 LTR without cirrhosis at baseline, only one (0.9%) developed liver cirrhosis 
compared with 13 “de novo” cirrhosis in NR/RR (21.3%, p<0.0001).  Three out of 8 (37.5%) LTR with 
cirrhosis at baseline showed a significant improvement of their liver stiffness; all of them were re-biopsed: 
two of them were classified as stage 4 according to Ishak's scoring system, the remaining patient as stage 5. 
Three patients developed HCC during follow up (1.6%, 95% CI: 0.42-6.29).  One out of 115  LTRs had HCC 
detected on ultrasound performed for his scheduled clinic visit 6 years after achieving SVR; two of the 67 
NR/RR developed HCC respectively 4.5 and 7 years after the end of therapy.  The risk of developing 
episodes of liver decompensation was very low: ascites was detected in only one NR during the follow-
up.  
At baseline, 24 patients (13.2%) showed IGF/DM; four of them were lost to follow-up.  
After a median follow-up of  9.2 years, the cumulative risk of IFG “de novo”(N= 17) or DM (N= 4) among the 
151 patients without baseline glucose abnormalities still in follow-up was 13.9% (95% CI 8.2-18.0).  The 
cumulative incidence of IFG or DM during follow-up is shown in Figure 1.   
Mean BMI of patients prior to therapy was 24±3.2; patients with a higher baseline BMI (>=24) showed a 
lower probability of achieving a LTR (OR= 0.47, 95% CI 0.23-0.98, p= 0.044) but this association was weaker, 
and no more statistically significant, when adjusted by other potential confounders (OR=0.67, p=0.375).   At 
the end of follow-up, LTR showed a mean weight increase of 0.80 Kg (range -0.31 / +1.92) compared to a 
mean weight loss of 0.55 (range -1.95 / + 0.85) observed among NR/RR (p= 0.13). 
In order to individuate baseline features predicting the incidence of IFG/DM during the long term follow-up 
we performed univariable log-rank test comparisons and a multivariable Cox proportional hazard 
regression analysis (Table 3): age >50 at diagnosis emerged as a strong  independent risk factor of  IFG/DM 
(HR 3.59, 95% CI 1.34-9.57, p= 0.011); high baseline viral load was significantly associated to development 
of glucose abnormalities, both at univariable analysis (p= 0.015) and after adjustment for age  in the Cox 
multivariable analysis (p= 0.0280).  Out of  106 LTRs without baseline IGF/DM, 15 developed glucose 
abnormalities (13 IFG and 2 DM) compared to 6 out of  45 NR (4 IFG and 2 DM, logrank p-value: 0.840).  
 
 
DISCUSSION 
The main finding of this long term prospective follow up study is that an SVR obtained with Peg-IFNalfa2b 
plus RBV in clinical practice is durable over the long term and that late viremic relapse is absent. 
Our data show that SVR rates achieved in the clinical setting are similar to those observed in randomized 
clinical trials, addressing the question of whether data obtained in randomized, controlled trials are 
representative for an average patient treated outside a major expert center.  A recent study (20) raised this 
issue showing that patients not included in therapeutic trials receiving the standard of care had more 
advanced liver disease, a more frequent history of psychiatric disorders and often were on drug-
substitution therapy.  In contrast to this finding, a prospective cohort study (21) demonstrated that 
treatment for HCV infection delivered in the community-based setting induced therapeutic results similar 
to those observed in academic medical centers. 
According to our results, patients with CHC treated with Peg-IFNalfa2b plus RBV in the clinical setting 
during the years 2001-2002 in different Centres of North Western Italy showed a high percentage of 
genotype 2-3 (46.2%) and this may account for the good therapeutic results obtained. 
The relatively high number of treated patients with favourable genotypes does not represent a selection 
bias but reflects the epidemiological distribution of HCV genotypes in this part of Italy (22).  Moreover, 
indications to treatment in 2001 were still influenced by the concern regarding the potential prolonged 
effect of Peg-IFN on neutrophils and platelets and this may account for the low number of cirrhotics 
included.   
In our study, LTR was accompanied by a significant decrease of cirrhosis incidence compared with NR/RR 
(0.9% vs 21.3%, p≤ 0.0001); however, liver decompensation among NR/RR with cirrhosis was rarely 
observed.  The relative good outcome found among NR/RR may appear surprising but it reflects the 
favourable baseline histologic features of patients included.  
At variance with previous studies which reported a significant improvement of HCC incidence in cirrhotics 
obtaining SVR (23-29), the relatively low number of cirrhotics at baseline and the very low number of those 
developing HCC did not allow us to analyze with sufficient statistical power this association. However, the 
incidence of HCC observed among our cirrhotics not responding to therapy was similar to that reported by 
a recent epidemiological review (30).  The results of our study stress the importance of continuing 
ultrasound monitoring  in cirrhotics, even though they obtain a long term viral eradication.     
Interestingly,  a >20% reduction of Peg-IFN dosage negatively influenced the LTR rate as  reported by  some 
re-treatment studies (31,32) while patients who received <80% of the total RBV dose showed a significantly 
higher rate of LTR, confirming the results of a previous study (33) where patients who required a RBV-dose 
reduction due to anemia had a higher rate of SVR.   
Our study failed to show a statistically significant lower incidence of  both IFG and DM in LTR compared to 
NRs, confirming our previous observations (16,34).  The discrepancy with the results obtained by other 
Authors (14,35) showing a decrease in the incidence of DM among SVRs may be explained by the different 
baseline features of our patients (low number of cirrhotics, predisposed to hepatogenous DM) and by the 
weight increase observed in our SVR.      The beneficial effect of SVR on insulin resistance (36,37) was 
probably counterbalanced by  the weight increase as previously demonstrated (36,38).  
Secondary aim of this study was to establish  if measurement of serum HCV-RNA at 12 weeks post-
treatment   to assess LTR was as relevant as at 24 weeks post-treatment in patients with an end of 
treatment response.  According to our data, 2 out of 16 (12.5%) relapsers were HCV-RNA-negative 12 
weeks after the end of treatment; these results were obtained by assays with a low sensitivity (50 IU/ml) 
but are similar to those reported by Kanda and coll. (11) who used more sensitive assays, suggesting that 
current definition of SVR is still appropriate. 
Our results may be affected by some methodological weaknesses. The main limitation was that we could 
not assess the clinical outcome of  11 (6%) NR/RR who were dropped out from the study.  We therefore 
cannot exclude the possibility that these patients may have developed cirrhosis and/or its complications or 
IFG/DM. Second, the number of recruited patients may not be sufficient to detect  as statistically significant 
small/medium effects; for this reason, larger prospective observational studies are needed to better 
establish the long-term effect of viral eradication in patients treated in the clinical practice.   
In conclusion, SVR achieved with PegIFN and RBV is durable among patients treated in the clinical setting 
and such patients may be considered cured from a virologic standpoint with the exception of cirrhotics who 
should be monitored for the risk of HCC.    LTR is associated with a significantly reduction of cirrhosis 
incidence but in patients with baseline mild  forms of HCV-related liver disease there is no clear evidence 
that LTR will result in significantly reduced morbidity and mortality compared  with NR/RR.   Conversely,  in 
a population predominantly composed by non-cirrhotic patients the incidence of glucose abnormalities is 
not significantly different between LTR and NR/RR over the long term.     
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Legend 
Figure 1. Cumulative incidence of IFG or diabetes during the follow-up in a cohort of 151 chronic 
hepatitis C patients 
 
 
 
Table 1. Baseline characteristics of the cohort and length of follow-up. 
 
 
   Normal values 
Age (years): mean (SD) 45.9 (12.4)  
    
Gender (males) : n (%) 109 (59.9)  
    
BMI: mean (SD): 24.0 (3.2)  
    
Fasting glucose (mg/dl): mean (SD) 90.9 (19.1) 70-100 
IFG: n (%) 16 (8.8)  
Diabetes mellitus: n (%) 8 (4.4)  
IFG or diabetes mellitus: n (%) 24 (13.2)  
    
Haemoglobin (g/dl): mean (SD) 14.7 (1.33) 13-17 
    
Leucocytes (x 103): mean (SD) 6.2 (1.6) 4.5-11 
    
Neutrophils (x 103): mean (SD) 3.3 (1.2) 1.8-9 
    
TSH (mU/l): mean (SD) 1.85 (1.1) 0.1-3.5 
    
ALT (IU): median (IQR) 94 (76) 10-35 
    
GGT (IU): median (IQR) 41.5 (49) 10-50 
    
Histology:    
Grading: mean (SD) 4.8 (2.2)  
Staging: mean (SD) 2.5 (1.2)  
Cirrhosis: n (%) 14 (7.7)  
    
Viral load (x 105 UI/ml): median (IQR) 7.8 (17.3)  
    
Viral genotype: n (%)    
1 87 (47.8)  
2 52 (28.6)  
3 32 (17.6)  
4 11 (6.0)  
    
Follow-up length (years): median (IQ range) 9.2 (9.0-9.5)  
Table 2. Clinical and virological features associated to long term virological response: univariable 
and multivariable logistic regression analyses 
 
   Univariable analysis Multivariable analysis 
 n/tot (%) OR (95% CI) p OR (95% CI) p 
Age group:         
< 50 75/111 (67.6) 1 - - 0.99
a 
(0.96-1.02) 0.525 
>=50 40/71 (56.3) 0.62 (0.34-1.15) 0.127 
Gender:         
Females 47/73 (64.4) 1 - - 1 - - 
Males 68/109 (62.4) 0.92 (0.50-1.70) 0.784 1.57 (0.70-3.56) 0.276 
BMI:         
<24 52/71 (73.2) 1 - - 1 - - 
>=24 35/62 (56.5) 0.47 (0.23-0.98) 0.044 0.67 (0.28-1.61) 0.375 
Missing 28/49 (57.1) 0.49 (0.22-1.06) 0.068 0.54 (0.21-1.37) 0.193 
IFG or diabetes mellitus:         
Absent 106/158 (67.1) 1 - - 1 - - 
Present 9/24 (37.5) 0.29 (0.12-0.72) 0.007 0.47 (0.16-1.33) 0.154 
Cirrhosis:         
Absent 107/168 (63.7) 1 - - 1 - - 
Present 8/14 (57.1) 0.76 (0.25-2.29) 0.626 0.94 (0.26-3.35) 0.925 
Viral load (UI/ml):         
< 800000 64/94 (68.1) 1 - - 0.80
 b 
(0.61-1.04) 0.094 
>=800000 51/88 (58.0) 0.65 (0.35-1.18) 0.158 
Viral genotype:         
2-3 71/84 (84.5) 1 - - 1 - - 
1-4 44/98 (44.9) 0.15 (0.07-0.30) <0.0001 0.16 (0.07-0.36) <0.0001 
Peg-IFN reduction (>20%):         
No 110/169 (65.1) 1 - - 1 - - 
Yes 5/13 (38.5) 0.34 (0.11-1.07) 0.065 0.32 (0.07-1.49) 0.146 
RBV reduction (>20%):         
No 91/150 (60.7) 1 - - 1 - - 
Yes 24/32 (75.0) 1.95 (0.82-4.62) 0.132 5.21 (1.54-17.67) 0.008 
 
a) Age in years 
b) Viral Load in log (UI/ml)  
Table 3. Clinical and virological features associated to incidence of IFG or diabetes during the 
follow-up: univariable logrank-test comparisons and multivariable Cox proportional hazard regression 
analysis. 
 
 Incident Cases/Total (%) 
Log-Rank Test 
(p-value) 
Cox Models 
HR
(a) 
(95% CI) p 
Age group:       
< 50 6/102 5.9  1 
(b) 
- - 
>=50 13/56 23.2 0.003 3.59 (1.34-9.57) 0.011 
Gender:       
Females 10/65 15.4  1 - - 
Males 9/93 9.7 0.327 0.87 (0.33-2.28) 0.777 
BMI:       
<24 7/65 10.8  1 - - 
>=24 10/50 20.0 0.110 1.71 (0.65-4.51) 0.279 
Missing 2/43 4.7  0.63 (0.13-3.15) 0.576 
Cirrhosis:       
Absent 16/147 10.9  1 - - 
Present 3/11 27.3 0.070 1.67 (0.44-6.36) 0.453 
Viral load (UI/ml):       
< 800000 5/86 5.8  1 
(c) 
- - 
>=800000 14/72 19.4 0.015 3.14 (1.13-8.71) 0.028 
Viral genotype:       
2-3 12/78 15.4  1 - - 
1-4 7/80 8.8 0.177 0.46 (0.18-1.19) 0.110 
Peg-IFN reduction (>20%):       
No 19/148 12.8  1 - - 
Yes 0/10 0.0 0.242 Not estimable   
RBV reduction (>20%):       
No 14/130 10.7  1 - - 
Yes 5/28 17.9 0.312 1.54 (0.55-4.27) 0.412 
Sustained virological response       
No 5/52 9.6  1 - - 
Yes 14/106 13.2 0.840 1.63 (0.57-4.65) 0.363 
 
Adjusted for age and baseline viral load (log transformed) as continuous variables, unless otherwise 
specified 
Adjusted for baseline viral load (log transformed) as continuous variable 
Adjusted for age, as continuous variable  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
